Lilly’s Alimta Increases Disease-Free Periods for Lung Cancer Patients

by Kathy Jones on  June 6, 2011 at 6:26 PM Cancer News
RSS Email Print This Page Comment
Font : A-A+

A phase-III study conducted by Eli Lilly and Co has found that the company's lung cancer drug, Alimta increased the progression free survival period among patients who suffered from advanced nonsquamous non-small cell lung cancer.
 Lilly’s Alimta Increases Disease-Free Periods for Lung Cancer Patients
Lilly’s Alimta Increases Disease-Free Periods for Lung Cancer Patients

The "Paramount" study involved more than 930 patients whose initial treatment involved four courses of Alimta and cisplatin.

The researchers then selected patients among whom the disease did not worsen and divided them into separate groups, each receiving either a daily dose of Alimta or a placebo.

The researchers found that those who were on Alimta did not exhibit any disease progression for 3.9 months compared to 2.6 months among those who were on placebo.

The company said that it will be approaching the Food and Drug Administration in the United States to approve Alimta as maintenance treatment among those who had been given the drug as part of their initial treatment.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Lung Biopsy Lung Cancer Malignant Mesothelioma Cancer and Homeopathy Cancer Facts Asbestosis Cancer Tattoos A Body Art Pneumoconiosis Smoking among Women 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive